Clinical

Dataset Information

0

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors


ABSTRACT: Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.

DISEASE(S): Neuroendocrine Tumors,Sclc,Pancreatic Adenocarcinoma,Carcinoma,Sarcoma,Malignant Solid Tumor,Tumori Solidi Avanzati Selezionati,Glioblastoma,Advanced Solid Tumors,Mesothelioma,Endometrial Neoplasms,Neoplasms,Colorectal Carcinoma,Soft Tissue Sarcoma (excluding Gist),Epithelial Ovarian Carcinoma,Gastric Carcinoma,Carcinoma, Ovarian Epithelial,Colorectal Neoplasms,Gastroenteropancreatic Neuroendocrine Tumor,Stomach Neoplasms,Endometrial Carcinoma,Selected Advanced Solid Tumors,Cancer

PROVIDER: 2202796 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-07-04 | PXD035060 | JPOST Repository
2025-03-14 | PXD061817 |
2017-09-18 | PXD007822 | JPOST Repository
2021-05-01 | PXD025170 | Pride
2014-10-25 | E-MTAB-2890 | biostudies-arrayexpress
2007-12-23 | GSE7362 | GEO
2007-12-23 | GSE7358 | GEO
2020-09-10 | GSE137269 | GEO
2022-11-02 | GSE156888 | GEO
2012-12-03 | E-GEOD-39426 | biostudies-arrayexpress